World's Best Scientists 2026 revealed!
Massimo Cristofanilli

Massimo Cristofanilli

D-Index & Metrics

Medicine

D-Index
120
Citations
67871
World Ranking
3691
National Ranking
2033

Overview

Massimo Cristofanilli is affiliated with Cornell University in the United States and has an extensive body of research primarily focused on oncology and cancer research. Their work contributes significantly to the fields of medicine as well as biochemistry, genetics, and molecular biology, with a notable emphasis on oncology and cancer-related studies.

Their research spans several specialized subfields, including oncology, cancer research, pulmonary and respiratory medicine, molecular biology, and pathology and forensic medicine. This multidisciplinary approach supports an in-depth exploration of cancer mechanisms, diagnostics, and treatments.

The main topics addressed in their research encompass:

  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Cancer Cells and Metastasis
  • HER2/EGFR in Cancer Research
  • Genetic Factors in Colorectal Cancer
  • Breast Cancer Treatment Studies
  • Cancer Immunotherapy and Biomarkers

Massimo Cristofanilli has published in several prominent scientific journals. Frequent publication venues include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • The Journal of Liquid Biopsy
  • Annals of Oncology

Their recent papers reflect ongoing contributions to breast cancer research and targeted therapies. Notable publications include:

  • "The Landscape of Targeted Therapies in TNBC," 2020, Cancers
  • "Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer," 2023, Journal of Clinical Oncology
  • "ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer," 2021, Nature Communications
  • "Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives," 2022, Cancer Treatment Reviews
  • "Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study," 2022, Clinical Cancer Research

The scientist collaborates frequently with other researchers. Regular co-authors include:

  • Lorenzo Gerratana
  • Carolina Reduzzi
  • Andrew A. Davis
  • William J. Gradishar
  • Ami N. Shah

Best Publications

  • Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

    Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis;Alison Stopeck

  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

    Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André

  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi

  • Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System

    Sabine Riethdorf;Herbert Fritsche;Volkmar Müller;Thomas Rau

  • Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

    Massimo Cristofanilli;Daniel F. Hayes;G. Thomas Budd;Mathew J. Ellis

  • Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

    Daniel F. Hayes;Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

    G. Thomas Budd;Massimo Cristofanilli;Mathew J. Ellis;Allison Stopeck

  • Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

    Francisco J. Esteva;Vicente Valero;Daniel Booser;Laura T. Guerra

  • Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification

    Andrew D. Seidman;Monica N. Fornier;Francisco J. Esteva;Lee Tan

  • Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors

    Valentina Guarneri;Kristine Broglio;Shu Wan Kau;Massimo Cristofanilli

  • Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

    Charlotte Fribbens;Ben O’Leary;Lucy Kilburn;Sarah Hrebien

  • Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer

    Rinath Jeselsohn;Roman Yelensky;Gilles Buchwalter;Gilles Buchwalter;Garrett Frampton

  • Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

    Manfred Kaufmann;Gunter von Minckwitz;Elefhterios P. Mamounas;David Cameron

  • International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

    S. Dawood;S. D. Merajver;P. Viens;P. B. Vermeulen

  • The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

    Ben O'Leary;Ben O'Leary;Rosalind J. Cutts;Yuan Liu;Sarah Hrebien

  • Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

    Marjorie C. Green;Aman U. Buzdar;Terry Smith;Nuhad K. Ibrahim

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
William J. Gradishar
William J. Gradishar Northwestern University
James M. Reuben
James M. Reuben The University of Texas MD Anderson Cancer Center
Naoto T. Ueno
Naoto T. Ueno University of Hawaiʻi Cancer Center
Leonidas C. Platanias
Leonidas C. Platanias Northwestern University
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Nicholas C. Turner
Nicholas C. Turner Royal Marsden NHS Foundation Trust
Thomas A. Buchholz
Thomas A. Buchholz The University of Texas MD Anderson Cancer Center
Savitri Krishnamurthy
Savitri Krishnamurthy The University of Texas MD Anderson Cancer Center
Anthony Lucci
Anthony Lucci The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine but want flexible and alternative routes, there are a growing number of online degrees and career pathways in health sciences. Many programs now cater to working professionals, career changers, and those seeking advanced roles without pausing their careers.

For registered nurses aiming for more autonomy, rn to np programs offer a seamless transition from RN to nurse practitioner roles entirely online. Nurses who already have an RN credential may also consider online rn to bsn programs no clinicals, which allow them to earn a bachelor's degree without on-site clinical requirements.

Beyond nursing, there are reputable options in broader health management and nutrition. Aspiring healthcare leaders can pursue a cahme-accredited online Master of Healthcare Administration for advanced management positions. Those interested in dietetics and wellness can earn a nutrition degree online to work in public health or nutrition counseling.

These flexible learning options help make professional advancement in healthcare more accessible than ever.

Best Scientists Citing Massimo Cristofanilli

Trending Scientists

Recently Published Articles